Clinical trial information
Select trial for more information
- Overview
- Clinical Trials
- Abbreviations
Target Overview
B-cell maturation antigen (BCMA) is universally expressed on malignant plasma cells.1 CD19 is expressed on both multiple myeloma cells and their progenitors2 and is a recognized target for other hematologic malignancies and autoimmune diseases.
Compound Overview
AZD0120 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy, dual-targeting B-cell maturation antigen (BCMA) and CD19, and manufactured on the novel FasT CAR-T cell platform.3 AZD0120 has been acquired from Gracell Biotechnologies.
Mechanism of Action
AZD0120 was formerly named GC012F, and next-generation manufacturing refers to the
FasTCAR platform.
References
1. Tai YT, Anderson KC. Immunotherapy. 2015;7(11):1187-1199. 2. Boucher K, Parquet N, Widen R, et al. Clin Cancer Res. 2012;18(22):6155-6168. 3. Du J, Fu W, Jiang H, et al. Poster presented at ASCO 2023.
Target Overview
B-cell maturation antigen (BCMA) is universally expressed on malignant plasma cells.1 CD19 is expressed on both multiple myeloma cells and their progenitors2 and is a recognized target for other hematologic malignancies and autoimmune diseases.
Compound Overview
AZD0120 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy, dual-targeting B-cell maturation antigen (BCMA) and CD19, and manufactured on the novel FasT CAR-T cell platform.3 AZD0120 has been acquired from Gracell Biotechnologies.
Mechanism of Action
AZD0120 was formerly named GC012F, and next-generation manufacturing refers to the
FasTCAR platform.
References
1. Tai YT, Anderson KC. Immunotherapy. 2015;7(11):1187-1199. 2. Boucher K, Parquet N, Widen R, et al. Clin Cancer Res. 2012;18(22):6155-6168. 3. Du J, Fu W, Jiang H, et al. Poster presented at ASCO 2023.
Clinical trial information
Select trial for more information
Arrange By
Selected Filter(s)
Abbreviations
BCMA
B-cell maturation antigen
CAR-T
chimeric antigen receptor T cell (therapy)
CAR-NK
Chimeric antigen receptor natural killer-cell therapy
CD19
cluster of differentiation 19
CNS
Central nervous system
CD38
Cluster of differentiation 38
CRR
Complete response rate
DKd
Daratumumab, carfilzomib, and dexamethasone
DPd
Daratumumab, pomalidomide, and dexamethasone
ECOG-PS
Eastern Cooperative Oncology Group performance status
HLA
human leukocyte antigen
IMWG
International Myeloma Working Group
IMiDs
Immunomodulatory drugs
Kd
Carfilzomib and dexamethasone
LOT
Line of therapy
MM
multiple myeloma
MRD
Minimal residual disease (often also termed measurable residual disease)
NCI
National Cancer Institute
neg
Negative
OS
Overall survival
ORR
Overall response rate
PD
Progressive disease
PFS
Progression-free survival
PI
Proteasome inhibitor
PVd
Pomalidomide, bortezomib, and dexamethasone
SCT
Stem cell transplantation
TCE
T-cell engager